Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29633594 | 1.00 | ERN1 (0.54) | ERN1MAPK10 | |
| SCHEMBL29633607 | 0.93 | ERN1 (0.52) | ERN1MAPK10 | |
| SCHEMBL24435785 | 0.93 | ERN1 (0.52) | ERN1MAPK10 | |
| SCHEMBL24435821 | 0.93 | ERN1 (0.52) | ERN1MAPK10 | |
| SCHEMBL25072021 | 0.88 | ERN1 (0.69) | ERN1MAPK10 | |
| SCHEMBL21910013 | 0.88 | ERN1 (0.69) | ERN1MAPK10 | |
| SCHEMBL30143050 | 0.88 | ERN1 (0.69) | ERN1MAPK10 | |
| Hydrochloric Acid SCHEMBL27237818 | 0.87 | ERN1 (0.69) | ERN1MAPK10 | |
| Hydrochloric Acid SCHEMBL27237812 | 0.87 | ERN1 (0.69) | ERN1MAPK10 | |
| SCHEMBL24439288 | 0.85 | ERN1 (0.47) | ERN1MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220153723-A1 | IRE1ALPHA INHIBITORS AND USES THEREOF | UNIVERSITY OF WASHINGTON | 2022-05-19 | — | — | US | disclosed |
| WO-2022104151-A1 | IRE1ALPHA INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220153723-A1 | IRE1ALPHA INHIBITORS AND USES THEREOF | XBP1, ERN2, ERN1 | ERN1 3/4885MAPK10 1017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.